Evidence map›Paper›PMID 32928833›Full record

ArticleBMJ case reports2020

Vemurafenib-induced pancreatitis in a patient with recurrent hairy cell leukaemia.

Su Yun Chung, Janice Gloria Shen, Cristina M Ghiuzeli

Open access · greenAbstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in BMJ case reports, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.1field-weighted citation impact, top 51% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 3 citations in OpenAlex.

  1. A deep learning framework forNational science review · 2025
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

Su Yun ChungDivision of Hematology-Oncology, Department of Medicine, Northwell Health, Manhasset, New York, USA.ORCID http://orcid.org/0000-0001-6741-8741
Janice Gloria ShenDivision of Hematology-Oncology, Department of Medicine, Northwell Health, Manhasset, New York, USA.
Cristina M GhiuzeliDivision of Hematology-Oncology, Department of Medicine, Northwell Health, Manhasset, New York, USA CGhiuzeli@northwell.edu.
Northwell Health · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Recent studies have shown that BRAF inhibitors, such as vemurafenib, are effective in inducing long periods of remission in relapsed hairy cell leukaemia. Acute pancreatitis is one of the rare complications that is reported with vemurafenib use. As severe pancreatitis can be life threatening, physicians should be vigilant of this side effect and promptly treat patients that develop clinical signs and symptoms while receiving vemurafenib. We present an interesting case of vemurafenib-induced pancreatitis that not only resolved but also did not recur after reintroduction of the drug at a reduced dose.

Indexed as

Aged, 80 and overAntineoplastic AgentsHumansLeukemia, Hairy CellMalePancreatitisVemurafenibAntineoplastic AgentsVemurafenibhaematology (drugs and medicines)malignant and benign haematologypancreatitissafetyunwanted effects / adverse reactions

Identifiers

PMID32928833
PMCPMC7490934
OpenAlexW3084793966

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.